Aimmune Therapeutics company information, Employees & Contact Information

Aimmune Shareholders' $27.5M Deal Over Sale To Nestle OK'd Law360

Nestlé to acquire Aimmune Therapeutics GlobeNewswire

Aimmune Therapeutics Announces Additional $200 Million Equity Investment by Nestlé Health Science Business Wire

Manufacturing processes of peanut ( Arachis hypogaea ) allergen powder-dnfp Frontiers

Nestle pays $2 billion to secure Aimmune's allergy treatment CNBC

Nestlé buys the rest of Aimmune, aiming to boost a struggling peanut allergy treatment BioPharma Dive

Aimmune Therapeutics begins Phase II trial of AR101 and dupilumab Clinical Trials Arena

FDA Approves Aimmune's Palforzia OIT, Allergist Program Soon to Begin Allergic Living

Nestlé plunks down $2.1B to acquire Aimmune and blockbuster hopeful peanut allergy med Fierce Pharma

Nestlé buys peanut-allergy treatment maker in $2.6B deal Food Dive

Nestlé bolsters food allergy portfolio with $2.6-billion deal for Aimmune FirstWord Pharma

Latham Advises Aimmune Therapeutics in its US$2.6 Billion Acquisition by Sociétés des Produits Nestlé S.A., Part of Nestlé Health Science Latham & Watkins LLP

Aimmune Therapeutics to Present Positive Results from Phase 3 POSEIDON Study of PALFORZIA Business Wire

Nestlé boosts investment as Aimmune preps launch of peanut allergy drug BioPharma Dive

With food allergies on the rise, biotech Aimmune is focusing on raising patients' tolerance CNBC

FDA Approves Aimmune’s PALFORZIA™ as First Treatment for Peanut Allergy Business Wire

FDA approves Aimmune drug as first treatment for peanut allergy BioPharma Dive

Allergy Partners Announces Collaboration with Aimmune Therapeutics to Provide PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] Directly to Patients Business Wire

Nestlé​ makes newly acquired Aimmune a stand-alone unit, appoints new CEO BioPharma Dive

Safety and Efficacy Increased Over Time in Patients with Peanut Allergy Business Wire

Years after $2B buyout, Nestlé ditches Aimmune's peanut allergy drug Palforzia Fierce Pharma

With $98M investment, Nestlé bumps up its Aimmune stake to 19% Fierce Biotech

Aimmune Wins FDA Approval for First Peanut Allergy Treatment BioSpace

Nestlé Snaps Up Outstanding Shares of Aimmune for $2.6 Billion BioSpace

ICER deems unapproved Aimmune, DBV peanut allergy drugs unaffordable, sparking backlash Fierce Pharma

Nestlé to Acquire Aimmune Therapeutics for $2.6B Genetic Engineering and Biotechnology News

FDA review of Aimmune drug put on hold due to government shutdown BioPharma Dive

Two biotechs vying for the first peanut allergy treatment have readouts coming soon. Here's what to expect statnews.com

Armed with Nestlé cash, Aimmune grabs experimental food allergy drug from Xencor Fierce Biotech

Nestle invests $200 million more in Aimmune after peanut allergy drug approval Reuters

Aimmune’s peanut allergy drug finally gets an approval timeline BioPharma Dive

Aimmune Therapeutics (AIMT) Stock Price, News & Analysis MarketBeat

Peanut Allergy Study Emphasizes Impact of Avoidance, Fear of Accidental Reaction Contemporary Clinic

Regeneron/Sanofi, Aimmune collaborate on peanut allergy combo test Fierce Biotech

Aimmune's controversial peanut allergy med has its FDA nod. Will it sell? Fierce Pharma

DBV Battles Aimmune for Share of Peanut Allergy Treatment Market Labiotech.eu

Aimmune Becomes Point Pharmaceutical Business for Nestlé BioSpace

Nestlé Acquires Aimmune Therapeutics Powder & Bulk Solids

Aimmune Therapeutics completes Florida facility BioPharma Dive

Aimmune to Advance Development of Newly-Licensed Asset with $200 Million Investment from Nestle BioSpace

New Peanut Allergy Treatment From Aimmune Side Effects Data businessinsider.com

Insitro boosts executive team with Aimmune development chief and Pfizer vet Fierce Biotech

Peanut allergy drug developer Aimmune to cut 75 jobs as parent Nestlé looks at selling signature drug The Business Journals

Nestlé is set to acquire Aimmune in deal worth $2.6bn PMLiVE

Nestlé Buying Peanut Allergy Therapy Provider Aimmune for $2.6B Food Manufacturing

Aimmune Therapeutics’ Peanut Allergy Immunotherapy Looks Promising in Phase III Trial BioSpace

EU authorises Aimmune’s peanut allergy treatment Palforzia PMLiVE

Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies GlobeNewswire

Aimmune Therapeutics, Inc. | $AIMT Stock | Shares Take A Tumble Down On Poor Earnings Numbers warriortradingnews.com